Physician profile
Jackson B Bruce
NPI 1063597243
$8,865.37
in general payments reported to CMS, 2019-2025
41 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $1,391 · 2021: $1,444 · 2022: $1,292 · 2023: $1,359 · 2024: $1,117 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $886.33 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $781.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $732.97 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $730.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $419.96 | 2019-2020 | |
| Pfizer INC. | $391.38 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $363.07 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.84 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $307.33 | 2019-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.99 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $286.29 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $232.44 | 2019-2024 | |
| Amgen INC. | $199.52 | 2019-2024 | Otezla, Repatha |
| Dexcom, INC. | $190.36 | 2020-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.